Switzerland
CHEurope
Regulatory Overview
Switzerland is regulated by the Swissmedic. The country has 1 documented regulatory pathway for accessing unapproved or unlicensed medicines, covering named patient programs, compassionate use schemes, and special access arrangements.
Regulatory Authority
Swissmedic
Regulatory Pathways (1)
Swissmedic allows compassionate use of medicines not yet authorised in Switzerland for patients with serious or life-threatening diseases under the Therapeutic Products Act.
Application Form: Swissmedic Compassionate Use Application
Legal Basis: Therapeutic Products Act (HMG/LPTh)
Eligibility: Serious or life-threatening condition with no locally registered alternative
Reference: Swissmedic Compassionate Use Guidance
Drugs Available (9)
| Drug | Access Route | Status | Lead Time |
|---|---|---|---|
| ruxolitinib | — | — | — |
| miglustat | — | — | — |
| Octreotide | — | — | — |
| tocilizumab | — | — | — |
| sirolimus | — | — | — |
| idebenone | — | — | — |
| Patisiran | — | — | — |
| bevacizumab | — | — | — |
| asciminib | — | — | — |
Switzerland
| ISO Code | CH |
| Region | Europe |
| Regulatory Authority | Swissmedic |
| Pathways | 1 documented |
| Drugs Available | 9 drug(s) |